Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. reported a net loss of $274.4 million for fiscal year 2025, compared to a net loss of $343.0 million in the prior year. Revenue was minimal at $36 thousand, while operating expenses totaled $269.4 million, primarily driven by research and development costs of $158.7 million and acquired in-process research and development expenses of $66.3 million. The company used $150.0 million in cash for operating activities, but generated $54.1 million from investing activities and $50.4 million from financing activities, resulting in a net decrease in cash of $45.5 million. Total assets stood at $340.1 million, with stockholders' equity of $248.2 million. The company continues to advance its clinical pipeline, including pivotal trials for ronde-cel in large B-cell lymphoma and Phase 1 development of LYL273 for metastatic colorectal cancer.

Key Takeaways